Literature DB >> 7769851

Nature of HLA-associated predisposition to childhood acute lymphoblastic leukemia.

M T Dorak1, G Owen, I Galbraith, N Henderson, D Webb, K I Mills, C Darke, A K Burnett.   

Abstract

A molecular analysis was carried out in 63 sequentially diagnosed childhood acute lymphoblastic leukemia (ALL) patients and 1011 controls to investigate the homozygosity rate for HLA-DR53. HLA-DR53 is associated with acute myeloblastic leukemia at the protein level, and our previous study has shown its association with early-onset chronic myeloid leukemia only in homozygous form at the DNA level. In the present study, the homozygosity rates for DR53 were 17.5 and 13.6% in patients and controls, respectively. Ten of the 11 homozygous patients were boys. In the common ALL group (n = 40), all seven DR53 homozygous patients were boys, and among 19 girls this genotype was not observed (P = 0.006). For males, homozygosity for DR53 revealed a relative risk (RR) of 3.29 (P = 0.008) for common ALL. Five of the 11 relapsed patients were homozygous for DR53. Heterozygous frequencies for HLA-DR53 were not different between patients and controls. Homozygosity for DR53 was associated with a very high relapse rate (45.5 vs 7.7%, P = 0.002, RR = 9.1). These results extended our findings in chronic myeloid leukemia and showed the recessive nature and the male predominance of the interactive HLA influence on the development of childhood leukemia. Molecular mimicry of an HLA-DR53 epitope by oncogenic (retro)viruses or putative susceptibility genes in linkage disequilibrium with HLA-DR53 may be responsible for this association.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769851

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  HLA antigens in Iranian patients with B-cell chronic lymphocytic leukemia.

Authors:  S M Moazzeni; A A Amirzargar; F Shokri
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Association between HLA-DQB1 gene and patients with acute lymphoblastic leukemia (ALL).

Authors:  Elias Orouji; Jalil Tavakkol Afshari; Zahra Badiee; Abbas Shirdel; Afrouz Alipour
Journal:  Int J Hematol       Date:  2012-03-21       Impact factor: 2.490

3.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

Review 4.  Genetic susceptibility to childhood leukaemia.

Authors:  Anand P Chokkalingam; Patricia A Buffler
Journal:  Radiat Prot Dosimetry       Date:  2008-10-15       Impact factor: 0.972

5.  HLA-associated susceptibility to childhood B-cell precursor ALL: definition and role of HLA-DPB1 supertypes.

Authors:  G M Taylor; A Hussain; T J Lightfoot; J M Birch; T O B Eden; M F Greaves
Journal:  Br J Cancer       Date:  2008-03-11       Impact factor: 7.640

6.  Evidence that an HLA-DQA1-DQB1 haplotype influences susceptibility to childhood common acute lymphoblastic leukaemia in boys provides further support for an infection-related aetiology.

Authors:  G M Taylor; S Dearden; N Payne; M Ayres; D A Gokhale; J M Birch; V Blair; R F Stevens; A M Will; O B Eden
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

Review 7.  Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence.

Authors:  Kevin Y Urayama; Pamela D Thompson; Malcolm Taylor; Elizabeth A Trachtenberg; Anand P Chokkalingam
Journal:  Front Oncol       Date:  2013-12-12       Impact factor: 6.244

8.  Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.

Authors:  Jayaram Vijayakrishnan; James Studd; Peter Broderick; Ben Kinnersley; Amy Holroyd; Philip J Law; Rajiv Kumar; James M Allan; Christine J Harrison; Anthony V Moorman; Ajay Vora; Eve Roman; Sivaramakrishna Rachakonda; Sally E Kinsey; Eamonn Sheridan; Pamela D Thompson; Julie A Irving; Rolf Koehler; Per Hoffmann; Markus M Nöthen; Stefanie Heilmann-Heimbach; Karl-Heinz Jöckel; Douglas F Easton; Paul D P Pharaoh; Alison M Dunning; Julian Peto; Frederico Canzian; Anthony Swerdlow; Rosalind A Eeles; ZSofia Kote-Jarai; Kenneth Muir; Nora Pashayan; Mel Greaves; Martin Zimmerman; Claus R Bartram; Martin Schrappe; Martin Stanulla; Kari Hemminki; Richard S Houlston
Journal:  Nat Commun       Date:  2018-04-09       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.